38937373|t|Effect of Apolipoprotein E isoforms on the Abundance and Function of P-glycoprotein in Human Brain Microvascular Endothelial Cells.
38937373|a|BACKGROUND: Individuals with Alzheimer's disease (AD) often require many medications; however, these medications are dosed using regimens recommended for individuals without AD. This is despite reduced abundance and function of P-glycoprotein (P-gp) at the blood-brain barrier (BBB) in AD, which can impact brain exposure of drugs. The fundamental mechanisms leading to reduced P-gp abundance in sporadic AD remain unknown; however, it is known that the apolipoprotein E (apoE) gene has the strongest genetic link to sporadic AD development, and apoE isoforms can differentially alter BBB function. The aim of this study was to assess if apoE affects P-gp abundance and function in an isoform-dependent manner using a human cerebral microvascular endothelial cell (hCMEC/D3) model. METHODS: This study assessed the impact of apoE isoforms on P-gp abundance (by western blot) and function (by rhodamine 123 (R123) uptake) in hCMEC/D3 cells. Cells were exposed to recombinant apoE3 and apoE4 at 2 - 10 microg/mL over 24 - 72 hours. hCMEC/D3 cells were also exposed for 72 hours to astrocyte-conditioned media (ACM) from astrocytes expressing humanised apoE isoforms. RESULTS: P-gp abundance in hCMEC/D3 cells was not altered by recombinant apoE4 relative to recombinant apoE3, nor did ACM containing human apoE isoforms alter P-gp abundance. R123 accumulation in hCMEC/D3 cells was also unchanged with recombinant apoE isoform treatments, suggesting no change to P-gp function, despite both abundance and function being altered by positive controls SR12813 (5 microM) and PSC 833 (5 microM), respectively. CONCLUSIONS: Different apoE isoforms have no direct influence on P-gp abundance or function within this model, and further in vivo studies would be required to address whether P-gp abundance or function are reduced in sporadic AD in an apoE isoform-specific manner.
38937373	10	26	Apolipoprotein E	Gene	348
38937373	69	83	P-glycoprotein	Gene	5243
38937373	87	92	Human	Species	9606
38937373	161	180	Alzheimer's disease	Disease	MESH:D000544
38937373	182	184	AD	Disease	MESH:D000544
38937373	306	308	AD	Disease	MESH:D000544
38937373	360	374	P-glycoprotein	Gene	5243
38937373	376	380	P-gp	Gene	5243
38937373	418	420	AD	Disease	MESH:D000544
38937373	510	514	P-gp	Gene	5243
38937373	537	539	AD	Disease	MESH:D000544
38937373	586	602	apolipoprotein E	Gene	348
38937373	604	608	apoE	Gene	348
38937373	658	660	AD	Disease	MESH:D000544
38937373	678	682	apoE	Gene	348
38937373	770	774	apoE	Gene	348
38937373	783	787	P-gp	Gene	5243
38937373	850	855	human	Species	9606
38937373	897	905	hCMEC/D3	CellLine	CVCL:U985
38937373	957	961	apoE	Gene	348
38937373	974	978	P-gp	Gene	5243
38937373	1024	1037	rhodamine 123	Chemical	MESH:D020112
38937373	1039	1043	R123	Chemical	-
38937373	1056	1064	hCMEC/D3	CellLine	CVCL:U985
38937373	1106	1111	apoE3	Gene	348
38937373	1116	1121	apoE4	Gene	348
38937373	1162	1170	hCMEC/D3	CellLine	CVCL:U985
38937373	1282	1286	apoE	Gene	348
38937373	1306	1310	P-gp	Gene	5243
38937373	1324	1332	hCMEC/D3	CellLine	CVCL:U985
38937373	1370	1375	apoE4	Gene	348
38937373	1400	1405	apoE3	Gene	348
38937373	1430	1435	human	Species	9606
38937373	1436	1440	apoE	Gene	348
38937373	1456	1460	P-gp	Gene	5243
38937373	1493	1501	hCMEC/D3	CellLine	CVCL:U985
38937373	1544	1548	apoE	Gene	348
38937373	1593	1597	P-gp	Gene	5243
38937373	1679	1686	SR12813	Chemical	MESH:C100355
38937373	1702	1709	PSC 833	Chemical	MESH:C070272
38937373	1759	1763	apoE	Gene	348
38937373	1801	1805	P-gp	Gene	5243
38937373	1912	1916	P-gp	Gene	5243
38937373	1963	1965	AD	Disease	MESH:D000544
38937373	1972	1976	apoE	Gene	348
38937373	Negative_Correlation	MESH:D000544	5243
38937373	Association	MESH:C100355	5243
38937373	Association	MESH:C070272	5243
38937373	Association	MESH:D000544	348

